Trial Profile
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms NAPAGE
- 27 Sep 2022 Status changed from active, no longer recruiting to discontinued.
- 13 Sep 2022 Final results(n=39) of >2 year median follow assessing safety and activity of gemcitabine and nab-paclitaxel (nab-pc) in advanced, relapsed soft tissue sarcoma presented at the 47th European Society for Medical Oncology Congress
- 29 Oct 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.